Portfolio Bldg Blck Wld Phrm &BtchIdxETF

Johnson & Johnson Reports Long-Term Data on TREMFYA for Ulcerative Colitis in QUASAR Extension Study

Siligmueller & Norvid Wealth Advisors LLC Acquired AbbVie Inc. Stocks in Q3

Eli Lilly Reports Positive Trial Results for Zepbound-Taltz Combination Therapy

Eli Lilly and Company to Participate in TD Cowen Health Care Conference

Edge Financial Advisors LLC Increases Stake in Eli Lilly and Co

Barclays Upgrades Eli Lilly and Company Stock Rating

Analysts break down Eli Lilly's 40% stock rally from August 2025 to February 2026

Competitor Novo Nordisk Nominates Former Lilly Executive to its Board, Intensifying Market Competition

Amgen receives rating upgrades from 18 analysts, target price increased

Eli Lilly secures a three-year tariff exemption in exchange for drug discounts and expanding U.S. manufacturing.

AbbVie Reports 2025 Fiscal Year Earnings and Leadership Transition

Barclays Sets Merck Target Price at $140 Per Share

NewEdge Wealth LLC Increases Merck Position by 16.4%

Eli Lilly and Company Stock Price Declines 1.4% Amid Valuation Concerns

Barclays initiates coverage on Eli Lilly with an 'Overweight' rating.

Broderick Brian C Increased Holdings in Eli Lilly

Mordor Intelligence report forecasts Insulin Delivery Market to hit $33.79B in 2026, driven by digital devices.

AstraZeneca's Fixed-duration Calquence Combination Therapy Approved in the US

Institutional Investor Salomon & Ludwin, LLC Increases Stake in Eli Lilly and Co

Google DeepMind's Isomorphic Labs Plans to Start Clinical Trials for AI-Designed Drugs in 2026, Collaborating with Eli Lilly and Others

Abits

Real Messenger

Mangoceuticals

Clean Energy Tech

Rackspace Tech

AIOS Tech

Ringcentral

Tandem Diabetes

Neo-Concept

Zeo Energy

PMCB

PBPH

<p>Pharmala Biotech Holdings Inc. has announced a change in its Board of Directors, with Dr. Malik Slassi resigning and Lennie Ryer, CPA, CA, being appointed as a new board member. This update is part of the company's ongoing governance adjustments.</p>

Reuters

PharmaCyte Biotech

Pharmala Biotech Appoints Lennie Ryer to Board as Malik Slassi Resigns

<p>Johnson & Johnson (JNJ) will report Q4 earnings on January 21, with analysts predicting revenue of $24.16 billion and earnings of $2.49 per share. Investors may consider ETFs like iShares U.S. Pharmaceuticals ETF (IHE) and Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) for exposure to JNJ without direct stock risk. The IHE ETF, which holds 23% of JNJ, has gained 28.09% over six months and has a Moderate Buy consensus rating with a price target suggesting 19.24% upside potential.</p>

Tip Ranks

iShares US Pharma

Johnson & Johnson

Looking for Exposure to Johnson & Johnson Stock (JNJ) ahead of Q4 Earnings? Here's How to Buy Without the Risk

Portfolio Bldg Blck Wld Phrm &BtchIdxETF(PBPH.US)

Pharmala Biotech Appoints Lennie Ryer to Board as Malik Slassi Resigns

Looking for Exposure to Johnson & Johnson Stock (JNJ) ahead of Q4 Earnings? Here's How to Buy Without the Risk